Skip to main content

Table 1 Comparative efficacy and safety between infliximab and vedolizumab in patients with Crohn’s disease

From: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Outcome Treatment Participants, N Infliximab, estimate (95% CI)a Heterogeneity (%)
Efficacy: Induction phase (Week 6)
CDAI-70 Infliximab 220 72% (66%, 77%) 0
Vedolizumab 214 45% (32%, 60%) 89
CDAI-100 Infliximab 273 62% (56%, 68%) 0
Vedolizumab 423 36% (29%, 44%) 68
Clinical remission Infliximab 611 38% (32%, 45%) 69
Vedolizumab 423 17% (12%, 24%) 71
Efficacy: Maintenance phase (Week 50 to 54)
CDAI-70 Infliximab 220 74% (68%, 79%) 0
CDAI-100 Infliximab 273 70% (64%, 75%) 0
Vedolizumab 148 44% (24%, 67%) 93
Clinical remission Infliximab 611 54% (48%, 60%) 57
Vedolizumab 148 39% (24%, 56%) 88
Safety (≤ 1 year)
Any AE Infliximab 717 75% (66%, 83%) 86
Vedolizumab 985 78% (59%, 90%) 98
Any SAE Infliximab 717 12% (8%, 17%) 65
Vedolizumab 993 16% (8%, 30%) 93
Any infection Infliximab 717 29% (22%, 37%) 80
Vedolizumab 427 17% (14%, 21%) 24
Any serious infection Infliximab 562 4% (2%, 6%) 0
Vedolizumab 985 4% (2%, 8%) 67
Discontinuation due to AE Infliximab 717 6% (3%, 12%) 79
Vedolizumab 976 7% (3%, 15%) 84
Discontinuation due to lack of efficacy Infliximab 311 6% (4%, 10%) 49
  1. a Random-effects model
  2. All results reported as the proportion of patients achieving the response
  3. AE Adverse event, CDAI Crohn’s disease activity index, CI Confidence interval, SAE Serious adverse event